Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.35 |
| ▸ | AKT2 | P31751 | 4/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102287 | 0.91 | PRKCI (0.53) | PRKCIAKT1JAK1NUDT1PBK | |
| SCHEMBL29541478 | 0.91 | PRKCI (0.53) | PRKCIAKT1JAK1NUDT1PBK | |
| Trifluoroacetic Acid SCHEMBL4096039 | 0.83 | PRKCI (0.47) | PRKCIAKT1JAK1NUDT1KLKB1 | |
| SCHEMBL4082749 | 0.77 | KCNJ1 (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL4082067 | 0.74 | PRKCI (0.54) | PRKCIJAK1NUDT1PBKGRM4 | |
| Trifluoroacetic Acid SCHEMBL4088934 | 0.73 | PRKCI (0.46) | PRKCIAKT1JAK1KLKB1GRM4 | |
| SCHEMBL3453092 | 0.73 | PRKCI (0.67) | PRKCIJAK1NUDT1PBKAKT2 | |
| Trifluoroacetic Acid SCHEMBL4082707 | 0.73 | PRKCI (0.52) | PRKCIJAK1KLKB1PBKGRM4 | |
| Trifluoroacetic Acid SCHEMBL4099482 | 0.73 | PRKCI (0.41) | PRKCIAKT1JAK1NUDT1KLKB1 | |
| Trifluoroacetic Acid SCHEMBL4095594 | 0.72 | PRKCI (0.51) | PRKCIAKT1JAK1PBKAKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PRKCI 304/4885AKT1 1142/4885JAK1 2/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PRKCI 304/4885AKT1 1142/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.